Silencing of polo-like kinase 2 increases cell proliferation and decreases apoptosis in SGC-7901 gastric cancer cells.

Li Ying Liu,Wei Wang,Ling Yu Zhao,Bo Guo,Juan Yang,Xiao Ge Zhao,Tu Sheng Song,Chen Huang,Ji Ru Xu
DOI: https://doi.org/10.3892/mmr.2014.3077
IF: 3.423
2015-01-01
Molecular Medicine Reports
Abstract:Polo-like kinase 2 (PLK2) is a serine/threonine protein kinase, which has vital roles during mitosis and the centrosome cycle. In acute myeloblastic leukemia and hepatocarcinogenesis, PLK2 acts as a tumor suppressor; however, the function of PLK2 in gastric cancer remains to be elucidated. In the present study, PLK2 was overexpressed in gastric cancer tissues and three types of gastric cancer cells, SGC-7901, MKN-45 and BGC-823. Transfection of SGC-7901 gastric cancer cells with small interfering (si)RNA against PLK2 exerted no effect on the ratio of cells at different stages of the cell cycle compared with that of the untransfected and control siRNA-transfected cells. In addition, silencing of PLK2 significantly enhanced the growth of SGC-7901 cells through inhibiting apoptosis. Furthermore, apoptosis-associated genes Bax and caspase 3 were found to be downregulated at the protein level. In conclusion, these results suggested that PLK2 may act as a tumor suppressor in gastric cancer, therefore indicating its therapeutic potential.
What problem does this paper attempt to address?